5-Methylaminomethyl-2-thiouridine 5'-monophosphate | 36357-42-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 5-Methylaminomethyl-2-thiouridine 5'-monophosphate
• 英文别名: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[5-(methylaminomethyl)-4-oxo-2-sulfanylidenepyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate
• CAS: 36357-42-3
• 化学式: C₁₁H₁₈N₃O₈PS
• 分子量: 383.32
• InChiKey: LVNQROXSHGRCLA-FDDDBJFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  193
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• Complexes of RNA and cationic peptides for transfection and for immunostimulation
  申请人：CureVac GmbH

  公开号：EP2484770A1

  公开（公告）日：2012-08-08

  The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x with the majority of the residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

  本发明涉及一种复合 RNA，包括至少一种与一种或多种寡肽复合的 RNA，其中寡肽的长度为 8 至 15 个氨基酸，具有经验式 (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x，大部分残基选自 Arg、Lys、His、Orn。本发明进一步涉及一种转染细胞或生物体的方法，从而应用本发明的复合 RNA。此外，本文还公开了包含本发明络合 RNA 的药物组合物和试剂盒，以及本发明络合 RNA 用于转染细胞、组织或生物体和/或调节、优选诱导或增强免疫反应的用途。
• cDNAs encoding polypeptides
  申请人：——

  公开号：US20030003471A1

  公开（公告）日：2003-01-02

  This invention relates to an isolated nucleic acid fragment encoding a phospholipase D. The invention also relates to the construction of a chimeric gene encoding all or a substantial portion of the phospholipase D, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the phospholipase D in a transformed host cell.

  本发明涉及一种编码磷脂酶 D 的分离核酸片段。本发明还涉及以有义或反义方向构建一种编码全部或大部分磷脂酶 D 的嵌合基因，其中表达该嵌合基因可导致在转化的宿主细胞中产生改变水平的磷脂酶 D。
• Methods and apparatuses for diagnosing AML and MDS
  申请人：Burczynski E. Michael

  公开号：US20050202451A1

  公开（公告）日：2005-09-15

  Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.

  诊断或监测 AML 或 MDS 进展或治疗的方法、系统和设备。本发明确定了多个急性髓细胞性白血病或骨髓增生异常综合症疾病基因，这些基因在急性髓细胞性白血病或骨髓增生异常综合症患者的骨髓细胞中与无病人类相比表达不同。这些 AML 或 MDS 疾病基因可用作检测是否患有 AML 或 MDS 的分子标记。这些基因还可用于早期识别最终发展为 AML 的 MDS 患者。
• Listeria monocytogenes genome, polypeptides and uses
  申请人：Buchrieser Carmen

  公开号：US20060078901A1

  公开（公告）日：2006-04-13

  The genome sequence and nucleotide sequences of Listeria monocytogenes EGD-e are provided. Polypeptide sequences, including surface or cell envelope polypeptides, and polypeptides involved in metabolism, including B12 biosynthesis, are also provided. Uses of these sequences are also provided.

  李斯特菌的基因组序列和核苷酸序列 李斯特菌 EGD-e 的基因组序列和核苷酸序列。还提供了多肽序列，包括表面或细胞包膜多肽，以及参与新陈代谢（包括 B12 生物合成）的多肽。还提供了这些序列的用途。
• Compositions and methods for identifying antiviral agents
  申请人：Devine E Scott

  公开号：US20060099583A1

  公开（公告）日：2006-05-11

  Disclosed are compositions and methods that can be used to identify antiviral compounds. The methods can be carried out by exposing a cell that expresses a host factor to a candidate compound. If the expression or activity of the host factor, which is a protein we identified by virtue of its influence on the endogenous retrovirus-like Ty1 element in yeast, is inhibited, the candidate compound is a potential antiviral agent. Such agents can be further tested, if desired, by determining whether they inhibit the ability of the virus to infect a cell or replicate within it.

  所公开的是可用于鉴定抗病毒化合物的组合物和方法。这些方法可以通过让表达宿主因子的细胞接触候选化合物来实现。如果宿主因子（我们通过其对酵母中内源性逆转录病毒样 Ty1 元件的影响而确定的一种蛋白质）的表达或活性受到抑制，候选化合物就是一种潜在的抗病毒剂。如果需要，还可以通过确定这些药剂是否能抑制病毒感染细胞或在细胞内复制的能力来进一步检测这些药剂。